ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -10 مورد

Comparison of international and American urticarial guidelines

Comparison of international and American urticarial guidelines
The approach of the 2022 international guideline (left side)[1] and the earlier American practice parameter (right side)[2] are compared.

AAAAI: American Academy of Allergy, Asthma, and Immunology; ACAAI: American College of Allergy, Asthma, and Immunology; EAACI: European Academy of Allergy and Clinical Immunology; fgAH: first-generation antihistamine; LTRA: leukotriene-receptor antagonist; sgAH: second-generation antihistamine; WAO: World Allergy Organization.

* Initial omalizumab dose: 300 mg every 4 weeks.

¶ Omalizumab dose can be increased up to 600 mg every 2 weeks.

Δ Different spellings as used in the respective guidelines.

References:
  1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77:734.
  2. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014; 133:1270.

Original figure modified for this publication. From: Zuberbier T, Bernstein JA. A comparison of the United States and international perspective on chronic urticaria guidelines. J Allergy Clin Immunol Pract 2018; 6:1144. Illustration used with the permission of Elsevier Inc. All rights reserved.

Graphic 118731 Version 2.0